Study of Human Monoclonal Antibody to Treat Mycosis Fungoides and Sezary Syndrome
The purpose of this study is to determine the efficacy of the drug, HuMax-CD4, in patients with mycosis fungoides(MF) and sezary syndrome who are intolerant to or do not respond to treatment with Targretin® and one other standard therapy.
Mycosis Fungoides|Sezary Syndrome
DRUG: HuMax-CD4 (zanolimumab)
PGA Score, Duration of Study
The purpose of this study is to determine the efficacy of the drug, HuMax-CD4, in patients with mycosis fungoides(MF) and sezary syndrome who are intolerant to or do not respond to treatment with Targretin® and one other standard therapy.